Status
ACTIVE
Global HQ
Sydney, Australia
Countries of investment
- Australia
- New Zealand
Investment stages
- Pre-Seed
- Seed
- Series A
Industries
- Medical devices
- MedTech
- Surgical robotics
- Diagnostics & imaging
- Oncology technology
- Neurotechnology
About
Bioshore Ventures is a Sydney-based specialist MedTech venture capital fund registered as an Early Stage Venture Capital Limited Partnership. Its investor base consists of clinicians, surgeons and senior MedTech executives, which the firm treats as its core differentiator in sourcing and diligence. Its team has founded, scaled and exited medical technology businesses across Australia, New Zealand and internationally.
Bioshore Ventures is a Sydney-based specialist MedTech venture capital fund registered as an Early Stage Venture Capital Limited Partnership. Its investor base consists of clinicians, surgeons and senior MedTech executives, which the firm treats as its core differentiator in sourcing and diligence. Its team has founded, scaled and exited medical technology businesses across Australia, New Zealand and internationally.
Investment Thesis
Bioshore Ventures invests exclusively in medical technology, with an explicit thesis that ambulatory surgery centres will increasingly displace hospital inpatient care, and that devices fitting that delivery model have a structural adoption advantage. They position themselves as "the D in R&D," backing technologies moving from research into clinical and commercial use, and argue that sector specialisation plus a clinician LP network produces superior risk-adjusted returns.
Manager's Experience
Sydney-based specialist MedTech fund, registered as an Early Stage Venture Capital Limited Partnership under Australia's Venture Capital Act 2002. General Partners are Jeff Reid, a MedTech founder and investor with a neuroscience background from Macquarie University; Andrew Fox-Smith, former Group President at Stryker, Chairman at Optimized Ortho and President-International at Enovis; and David Bottomley, with 25+ years in venture capital and capital markets, co-founder of Ryder Capital and managing general partner of the Ryder Innovation Fund. The investment committee includes Robert Cusack, CEO of the North Shore Network, and Dr Jonothon Brock, Co-Head of Anaesthesia at Royal North Shore Hospital, with Anne O'Neill, Andrew T Rock and Will Knox on the advisory board. Its LP base of clinicians, surgeons and senior MedTech executives is its stated core differentiator.
Team
Jeff Reid-General Partner
Andrew Fox-Smith-General Partner
David Bottomley-General Partner
Robert Cusack-Investment Committee
Dr Jonothon Brock-Investment Committee
Anne O'Neill-Advisory Board
Andrew T Rock-Advisory Board
Will Knox-Advisory Board
Portfolio
Leo Cancer Care
Remedy Robotics
Kitea Health
NanoMedX
Wellumio
Vexev
Tutelix
MedLogical Innovations